 | | PRD_000468 | | Name: | Allosamidin | | Formula: | C25 H42 N4 O14 | | Definition date: | 2015-07-18 | | Last modified: | 2022-03-03 |
|
 | | PRD_000041 | | Name: | (2S,3S,4R,5R,6R)-5-AMINO-2-(AMINOMETHYL)-6-((2R,3R,4R,5S)-4-(2-(3-AMINOPROPYLAMINO)ETHOXY)-5-((1R,2R,3S,5R,6S)-3,5-DIAM
INO-2-((2S,3R,4R,5S,6R)-3-AMINO-4,5-DIHYDROXY-6-(HYDROXYMETHYL)-TETRAHYDRO-2H-PYRAN-2-YLOXY)-6-HYDROXYCYCLOHEXYLOXY)-2-(
HYDROXYMETHYL)-TETRAHYDROFURAN-3-YLOXY)-TETRAHYDRO-2H-PYRAN-3,4-DIOL | | Formula: | C28 H57 N7 O14 | | Definition date: | 2017-07-12 | | Last modified: | 2022-03-02 |
|
 | | PRD_000042 | | Name: | (2S,3S,4R,5R,6R)-5-AMINO-2-(AMINOMETHYL)-6-((2R,3R,4R,5S)-5-((1R,2R,3S,5R,6S)-3,5-DIAMINO-2-((2S,3R,4R,5S,6R)-3-AMINO-4
,5-DIHYDROXY-6-(HYDROXYMETHYL)-TETRAHYDRO-2H-PYRAN-2-YLOXY)-6-HYDROXYCYCLOHEXYLOXY)-2-(HYDROXYMETHYL)-4-(2-((R)-PIPERIDI
N-3-YLMETHYLAMINO)ETHOXY)-TETRAHYDROFURAN-3-YLOXY)-TETRAHYDRO-2H-PYRAN-3,4-DIOL | | Formula: | C31 H61 N7 O14 | | Definition date: | 2017-07-12 | | Last modified: | 2022-03-02 |
|
 | | PRD_000043 | | Name: | DOUBLY FUNCTIONALIZED PAROMOMYCIN PM-II-162 | | Formula: | C37 H65 N7 O16 | | Definition date: | 2017-07-12 | | Last modified: | 2022-03-02 |
|
 | | PRD_002479 | | Name: | Cyclic Peptide Inhibitor ZO1-GLN-SER-TPO-45W-MLL | | Formula: | C34 H48 F3 N6 O14 P | | Definition date: | 2022-03-02 | | Last modified: | 2022-03-02 |
|
 | | PRD_002486 | | Name: | N,N-dimethyl-L-valyl-L-leucyl-N-[(3S)-6-{(2S)-2-[([1,1'-biphenyl]-4-yl)methyl]-3-methoxy-5-oxo-2,5-dihydro-1H-pyrrol-1-yl}-6-oxo-1-phenylhexan-3-yl]-L-leucinamide | | Formula: | C49 H67 N5 O6 | | Definition date: | 2022-03-02 | | Last modified: | 2022-03-02 |
|
 | | PRD_002487 | | Name: | N,N-dimethyl-L-valyl-L-leucyl-N-[(3S)-6-{(2S)-2-[(1H-indol-3-yl)methyl]-3-methoxy-5-oxo-2,5-dihydro-1H-pyrrol-1-yl}-6-oxo-1-phenylhexan-3-yl]-L-leucinamide | | Formula: | C45 H64 N6 O6 | | Definition date: | 2022-03-02 | | Last modified: | 2022-03-02 |
|
 | | PRD_000323 | | Name: | (2S)-2-[(2-amino-1,3-thiazol-4-yl)methyl]-N~1~-[(1S,2R,3R)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-N~4~-[2-(d
imethylamino)-2-oxoethyl]-N~4~-[(1S)-1-phenylethyl]butanediamide | | Formula: | C34 H53 N5 O5 S | | Definition date: | 2012-12-12 | | Last modified: | 2022-03-02 |
|
 | | PRD_000353 | | Name: | (2S)-2-[(2-amino-1,3-thiazol-4-yl)methyl]-N~1~-{(1S,2S)-1-(cyclohexylmethyl)-2-hydroxy-2-[(3R)-1,5,5-trimethyl-2-oxopyrrolidin-3-yl]ethyl}-N~4~-[2-(dimethylamino)-2-oxoethyl]-N~4~-[(1S)-1-phenylethyl]butanediamide | | Formula: | C36 H54 N6 O5 S | | Definition date: | 2012-12-12 | | Last modified: | 2022-03-02 |
|
 | | PRD_000204 | | Name: | Vancomycin | | Formula: | C66 H75 Cl2 N9 O24 | | Description: | VANCOMYCIN IS A TRICYCLIC GLYCOPEPTIDE, GLYCOSYLATED BY A DISACCHARIDE (RESIDUES 8 AND 9) ON RESIDUE 4. | | Definition date: | 2012-12-12 | | Last modified: | 2022-01-06 |
|
 | | PRD_002455 | | Name: | D-PMI-omega | | Formula: | C82 H115 Cl N17 O20 | | Definition date: | 2021-11-17 | | Last modified: | 2021-11-17 |
|
 | | PRD_002454 | | Name: | Substrate-like cysteine protease inhibitor | | Formula: | C46 H70 Cl N10 O9 | | Definition date: | 2021-09-01 | | Last modified: | 2021-09-01 |
|
 | | PRD_002469 | | Name: | Inhibitor 18 | | Formula: | C30 H42 N4 O6 | | Definition date: | 2021-08-25 | | Last modified: | 2021-08-25 |
|
 | | PRD_002459 | | Name: | dodecyl 6-O-alpha-D-galactopyranosyl-beta-D-glucopyranoside | | Formula: | C24 H46 O11 | | Definition date: | 2021-08-04 | | Last modified: | 2021-08-04 |
|
 | | PRD_002457 | | Name: | beta-D-glucopyranose-(1-4)-beta-D-glucopyranose-(1-3)-2-deoxy-2-fluoro-alpha-D-glucopyranose | | Formula: | C18 H31 F O15 | | Definition date: | 2021-05-19 | | Last modified: | 2021-05-19 |
|
 | | PRD_002377 | | Name: | (12S,15S)-N-[(2-fluorophenyl)methyl]-10,13-dioxo-12-{2-oxo-2-[(2R)-2-phenylpyrrolidin-1-yl]ethyl}-2-oxa-11,14-diazatricyclo[15.2.2.1~3,7~]docosa-1(19),3(22),4,6,17,20-hexaene-15-carboxamide | | Formula: | C39 H39 F N4 O5 | | Definition date: | 2021-04-28 | | Last modified: | 2021-04-28 |
|
 | | PRD_002383 | | Name: | des4.3.1 | | Formula: | C44 H74 N12 O11 S | | Definition date: | 2021-04-28 | | Last modified: | 2021-04-28 |
|
 | | PRD_002362 | | Name: | GsIN-1 peptide | | Formula: | C79 H106 N16 O21 S | | Definition date: | 2021-04-21 | | Last modified: | 2021-04-21 |
|
 | | PRD_002397 | | Formula: | C41 H72 N14 O10 S | | Definition date: | 2021-03-31 | | Last modified: | 2021-03-31 |
|
 | | PRD_002398 | | Formula: | C42 H74 N14 O10 S | | Definition date: | 2021-03-31 | | Last modified: | 2021-03-31 |
|
 | | PRD_002399 | | Formula: | C45 H68 N10 O11 S | | Definition date: | 2021-03-31 | | Last modified: | 2021-03-31 |
|
 | | PRD_002360 | | Name: | myristoyl thiourea inhibitor, No. 23 | | Formula: | C37 H67 N9 O5 S | | Definition date: | 2021-03-24 | | Last modified: | 2021-03-24 |
|
 | | PRD_002361 | | Name: | myristoyl thiourea inhibitor, No.13 | | Formula: | C39 H73 N12 O5 S | | Definition date: | 2021-03-24 | | Last modified: | 2021-03-24 |
|
 | | PRD_002460 | | Formula: | C20 H39 N3 O5 | | Description: | Calpain I inhibitor | | Definition date: | 2021-02-24 | | Last modified: | 2021-02-24 |
|
 | | PRD_900134 | | Name: | Blood group B H type 2 antigen, beta anomer | | Formula: | C26 H45 N O20 | | Description: | oligosaccharide with branches | | Definition date: | 2021-02-17 | | Last modified: | 2021-02-17 |
|
